Introduction
============

Tuberculosis(TB), caused by *Mycobacterium tuberculosis* (*Mtb*), remains a leading cause of morbidity and mortality globally [@B1]. The chronicity of tuberculosis mirrors the complex interaction between the pathogen and the host [@B2]. The HIV coinfection and emergency of multidrug and extensive drug resistant *Mtb* further exacerbated the predicament of tuberculosis control [@B3]. *Mycobacterium bovis*Bacillus Calmette-Guerin (BCG), the only vaccine available for TB, was plagued by its limited and sometime unstable efficacy [@B4].

Cytokines are critical for immunity against foreign invaders [@B5]. The interleukin (IL)-10 family of cytokines includes six immune mediators (IL-10, IL-19, IL-20, IL-22, IL-24 and IL-26) with similar protein motif, receptor complex and conserved signaling cascades [@B6], [@B7]. Their biological effect is diverse and widely ranges from anti-inflammatory to pro-inflammatory [@B6]. Two subfamilies exist based on the biological effect, immune regulatory cytokines including IL-10 only, and IL-20 subfamily consisting of the remaining five members (IL-19, IL-20, IL-22, IL-24 and IL-26) [@B8]. The genes encoding IL-10, IL-19, IL-20 and IL-24 are located on the chromosome 1q32 [@B6]. Whereas, IL-22 and IL-26 encoding genes cluster with IFN-gamma gene on the chromosome 12q15 [@B6]. IL-10 signals via IL-10RA/IL-10RB [@B9] and results in the phosphorylation of Stat3, a critical transcription factor for the immunosuppressive effect of IL-10 [@B10]. IL-19, IL-20 and IL-24 induced their signaling through the IL-20RA/IL-20RB receptor complex. However, IL-20 and IL-24 preferentially engage with the IL22RA1/IL-20RB receptor complex. IL-22 and IL-26 function via receptor complex consisting of IL-22RA1/IL-10RB or IL-20RA/IL-10RB [@B11]. Interestingly, IL-20 subfamily can also activate Stat3, but the outcome is different from the activation of IL-10 [@B11]. The molecular mechanisms underlying the diverse effect of Stat3 signaling remain poorly understood.

The role of IL-10 family of cytokines in tuberculosis has been addressed recently [@B12]-[@B16]. Here we discussed the roles of IL-10, IL-22, IL-24 and IL-26 in the context of tuberculosis.

Cellular source and *mycobacterial* regulation of IL-10 family of cytokine
==========================================================================

IL-10 can be produced by hematopoietic and non-hematopoietic cells in response to *Mycobacterium tuberculosis*Complex infection (Figure [1](#F1){ref-type="fig"}). BCG can activate the pattern recognition receptor (PRR) on the surface of alveolar epithelial cells. The engagement of TLR2 and TLR4 on surface of epithelial cells by BCG can activate the glycogen synthase kinase-3 (GSK3) by PI3K-Akt and promote the production of IL-10 and IL-22 [@B17]. However, conflicting evidence is that the suppression of GSK3 by chemical inhibitor can significantly boost the BCG induction of IL-10 derived from macrophages [@B18].

In neutrophils, coactivation of TLR2-MyD88- and C-type lectin receptor (CLR)- spleen tyrosine kinase (Syk)-dependent pathways led to the phosphorylation of p38 MAP and Akt kinases and subsequently, the upregulation of IL-10 [@B19].

The interaction between the BCG-infected dendritic cells (DCs) with neutrophil through CD11b can activate MyD88 and Syk, to produce large quantities of IL-10 [@B20].

*Mtb* can upregulate the IL-10 production via TLR2- ERK pathway [@B21]. Activation of ERK by*Mtb* Rv1265 was critical for induced IL-10 expression in macrophages [@B22]. Binding of the *Mtb* heat shock protein 60 to the TLR2 can activate macrophage p38 MAPK to increase the IL-10 production [@B23]. Similarly, the engagement of *Mtb* PPE32 with TLR2 can upregulate the IL-10 production via co-activation of NF-κB and MAPK [@B24]. Taken together, TLR2 and its downstream signaling MAPK pathway are essential for the induction of IL-10 expression in myeloid cells in response to the *M. tuberculosis* infection [@B25].

TLR3 regulates IL-10 expression in response to Mycobacterial-RNA through the PI3K/AKT signaling pathway [@B26]. BCG*-*stimulated IL-10 expression in human macrophages by activation of dsRNA-activated serine/threonine protein kinase (PKR), which in turn activates MAPK and NF-κβ [@B27].

*Mtb*promoted chemokine receptor 5 (CCR5) expression in macrophages, which in turn increased IL-10 production [@B28].

It was found that IFN-α can induce IL-10 production by macrophages through the phosphorylation of Stat1 [@B29]. IFN-α/β can induce IL-10 production by *Mtb*-infected macrophages [@B30]. This was supported by a murine study demonstrating that suppression of IFN-α/β by TPL-2-ERK1/2 signaling led to inhibition of IL-10 production [@B31].

*Mtb* infected antigen-presenting cells (APCs) can activate DAP12 (DNAX-activating protein of 12kDa) required for IRAK-M (interleukin-1 receptor-associated kinase M) expression, which in turn induces IL-10 production [@B32]. BCG can enhance the production of IL-10 by binding to the DC-SIGN in DCs [@B33]. Similarly, Mannose-capped lipoarabinomannan (Man-LAM) can induce IL-10 production through targeting the Dectin-2 in APCs [@B34]. BCG induced high levels of IL-10 production by cord blood DCs via upregulation of the nuclear transcription factor Rel-B [@B35].

*Mtb* can induce IL-10 production by CD8+ T cells [@B36], [@B37] {Cyktor, 2013 \#1}{Cyktor, 2013 \#1}. CD4+ T cells produced high levels of IL-10 in response to purified protein derivative (PPD) [@B38].

IL-22 is produced by cells of the lymphoid lineages in response to Mycobacteria, which includes CD4+ cells (Th17 and Th22) [@B39], [@B40] and natural killer (NK) cells [@B41] (Figure [1](#F1){ref-type="fig"}).

Stimulation of NK cells with *Mtb* in the presence of IL-15 led to DAP10 expression and subsequently, IL-10 production [@B42]. *Mtb* PstS1 upregulated IL-22 secretion from memory CD4+ T was mediated via DCs [@B43].

However, regulatory B cells can suppress IL-22 production [@B44]. The production of IL-22 showed significant increase in the absence of IFN-γ [@B45].

IL-24 is mainly produced by monocytes and activated T cells [@B46], [@B47](Figure [1](#F1){ref-type="fig"}).

IL-26 is produced by myeloid and lymphoid lineages of white blood cells in response to *Mtb* infection [@B13](Figure [1](#F1){ref-type="fig"}). IL-26 can be released by Th17 [@B48], [@B49], Th1 cells [@B48] and NK cells [@B50]. However, how*Mtb* or its antigens regulate the expression of IL‑22, IL-24 and IL-26 remains to be elucidated.

Role of IL-10 family in *Mycobacterial*immune evasion
=====================================================

IL-10 is a potent immunoregulatory cytokine indispensable for the host immunity against *mycobacteria* infection (Figure [2](#F2){ref-type="fig"}). Consistently, IL-10 transgenic mice fail to control *Mtb* infection and develop severe lung pathology compared with nontransgenic littermates [@B51]. However, IL-10-knockout mice were more resistant to *Mtb* infection and can limit bacterial growth within lung and spleen in comparison with the wild type [@B52]. Blocking of murine IL-10 signaling during *Mtb* infection was beneficial for the control of the growth of bacteria and enhanced the survival of mice [@B53]. It was shown that IL-10 -/- mice exhibited stronger Th1 responses during *Mtb* infection with concomitant massive pulmonary inflammation [@B54]. However, conflicting data is reported on the immunomodulatory effect of IL-10 during *Mycobacterial*infection. IL-10 transgenic mice show normal Th1 response to *Mtb* infection, but IL-10 can reduce the production of antimicrobials reactive nitrogen intermediates (NO) by macrophages via increased arginase-1 (arg1) expression. This led to the progression of the disease and earlier death of mice [@B55]. Furthermore, the expression of arg1 in hypoxic granuloma regions led to decreased T cells expansion [@B56].

The absence of IL-10 enhanced the production of IL-17, and resulted in excessive lung inflammatory response [@B12]. Similarly, blockade of IL-10 during BCG vaccination can increase the protection against *Mtb* challenge in both susceptible and comparatively resistant strains of mice due to enhanced Th17 cell responses [@B57]. IL-10 can repress 17A production through direct interacting with IL-10Rαin Th17 cell [@B20]. IL-17A deficient mice failed to develop mature granuloma and protective responses against virulent *Mtb* infection [@B58]. However, IL-10-deficient mice infected with *Mtb* can generate mature fibrotic pulmonary granulomas and improve the control of bacterial growth in the lungs [@B16]. Furthermore, IL-10 suppresses TNF-α production [@B30], [@B59], [@B60], TNF-αis essential for granulomas formation and blocking of TNF-αsignaling leads to the disintegration of granuloma and dissemination of *Mtb* [@B61]. Moreover, IL-10 can suppress the formation of multi-nucleated giant cells (MGC) from monocytes of TB patients in response to PPD [@B62], the histologic hallmark of granuloma which can limit*Mtb* infection. Taken together, the data suggest that IL-10 promotes the persistence and survival of pathogens. Therefore, the modulation of IL-10 levels might facilitate the TB elimination.

Peripheral blood mononuclear cells (PBMCs) obtained from multi-drug resistant TB patients stimulated by ESAT6 displayed a lower frequency of IFN-γ-producing T cells and a higher frequency of regulatory T cells (Treg) correlated with increased IL-10 secretion, when compared with cells from non-tuberculous *Mycobacteria* patients. Blockage of IL-10 or IL-10Rα with antibody can enhance Th1 responses and decreases the Treg cells [@B63].

Macrophages apoptosis is important for the cross-priming of T cells by DCs. DCs can uptake the apoptotic vesicle from the infected apoptotic macrophages and subsequently prime the naïve T cells [@B64]. IL-10 can suppress *Mtb*-induced macrophages apoptosis by reducing TFN-αand upregulating of Bcl3, an inhibitor of NF-κB activity [@B60]. Similarly, inhibition of macrophages apoptosis by virulent *M. bovis*was shown to be correlated with increased IL-10 and Bcl2 production and decreased TNF-α production [@B65]. Taken together, *Mycobacteria* can subvert the apoptosis of macrophages for better survival and persistence.

IL-10 can inhibit the production of IL-12 in *Mtb*-infected macrophage*s* [@B30]. IL-10 can interfere with antigen presentation by inducing MARCH1 member of ubiquitin ligase family that interacts and degrades class II major histocompatibility complex (MHC-II) molecules [@B66]. It has been shown that IL-10 pretreated monocyte-derived macrophages (MDMs) failed to traffic the*Mtb* peptide-MHC-II complexes to the plasma membrane [@B67]. IL-10 also inhibits MHC-II expression in *Mtb*-infected macrophages via activation of Stat3 [@B28]. Suppression of IL-12 and MHC-II by IL-10 in *Mtb*-infected macrophages led to compromised the Th1 responses [@B21]. Consistently, blocking of IL-10 signaling in *Mtb*-infected macrophages can enhance IL-12 secretion and augment the IFN-γ production by CD4+ T cells [@B68].

IL-10 also can enhance *Mtb* survival and growth in macrophages by suppressing phagosomal maturation partially dependent on Stat3 activation [@B69]. Taken together, IL-10 enhances *mycobacterial*intracellular survival and growth by suppressing innate and adaptive immune response.

The role of IL-26 in host defense against *Mtb* has been explored very recently (Figure [2](#F2){ref-type="fig"}). The possible role of IL-26 in *Mtb* infection has been demonstrated by *ex vivo* study [@B13]. Levels of IL-26 are lower in the *Mtb*-infected monocytes supernatants from TB patients than from healthy control [@B13]. The addition of recombinant IL-26 to whole blood infected with *Mtb* led to enhanced bacterial survival and growth [@B13]. However, how *Mtb*downregulates IL-26 and its role in antimycobacterial response remain to be explored.

IL-26 has quite unexpected cationic antimicrobials peptides properties that can lyse extracellular bacteria by forming membrane-pore [@B70]. Also, it can bridge the released bacterial DNA and TLR9, thereby triggering the production of type I IFN by plasmacytoid DCs [@B70]. IFN-α/β are potent inhibitors of the IFN-γ responsiveness and the production of type I cytokines that are required for protection against *Mtb* infection [@B48].

IL-26 produced by alveolar macrophages can recruit the neutrophils via induction of chemotaxis factors such IL-8 and leukotaxin n-formyl-methionyl-leucyl-phenylalanine (fMLP) [@B71]. IL-26 also can inhibit random migration (chemokinesis) of neutrophils [@B71]. Depletion of the neutrophil at the onset of TB infection results in significant increase the numbers of IFN-γ-producing CD4 T-cells, correlated with reduced bacterial load and lung pathology [@B72]. In-depth understanding of IL-26 biology is crucial to the development of immune intervention against tuberculosis.

Role of IL-10 family in immune protective against *Mycobacteria* infection
==========================================================================

It was predicted that the production of low levels of IL-10 by activated macrophages is required to an efficient antimicrobial response, control of bacterial growth and to prevent lung damage [@B73]. Therefore, modulation of IL-10 levels during TB therapy might shorten the duration of the treatment and accelerate the bacterial clearance.

IL-22 is crucial for tissues modulation in responses to inflammation. It induces proliferative and anti-apoptotic pathways, as well as anti-microbial substances, that can enhance tissue repair and prevent its damage [@B11].

IL-22 has been shown to be significantly upregulated in the blood from juvenile rhesus monkeys with severe TB disease [@B74]. IL-22-producing T cells were found most frequent localized in lungs than in blood and lymphoid tissue, and involved in granuloma formation in macaque TB model [@B15]. Interestingly, IL-22 was found to be most significantly upregulated in PBMCs from vaccinated-protected cattle, when compared with vaccinated-unprotected and unvaccinated control, suggested that IL-22 a potential biomarker for vaccine success [@B75]. IL-22-deficient mice display normal response to *Mtb* infection [@B76]. However, IL-22 may trigger the recruitment of B cells to the lungs by upregulating CXCL13 expression [@B77]. B cells play crucial roles in host defense by reducing inflammation and containment of *Mtb* [@B78]. IL-22-knockout mice challenged with *Mtb*exhibited smaller B cell follicles in comparison with the counterpart [@B77].

Administration of IL-22 into the mice at the time of BCG vaccination led to reduced bacterial burden and enhanced CD4+ T cell responses after *Mtb* challenge [@B41].

A polymorphism (rs2227473) in the IL-22 promoter was shown to be associated with TB susceptibility in Chinese populations [@B79]. IL-22 producing CD4+ T cells (Th22 ) frequencies were lowered in PBMCs from TB pleurisy (PTB) patients in comparison with healthy, whereas, IL-22 was detected in high concentration in bronchoalveolar lavage (BAL) fluid obtained from TB patients [@B80]. Likewise, the Th22 cells are elevated in tuberculous pleural fluid [@B40], [@B81], suggested that IL-22 does involve in immunity at local site of *Mtb*infection. In HIV patients with TB disease, IL-22 was differentially induced in PBMCs collected from TB with reconstitution inflammatory syndrome (TB-IRIS) after *in vitro* stimulation with *Mtb*, and higher concentration of IL-22 proteins was detected in their serum, when compared with non-IRIS patients [@B82]. Taken together, these data suggest that IL-22 might play a decisive role in tuberculosis immunity.

Modern Beijing strains can stimulate PBMCs from healthy individuals to produce lower level of IL-22 than the ancient Beijing and Euro-American strains [@B83]. Manipulation of IL-22 level by *Mtb* modern Beijing strains might benefit its intracellular survival.

IL-22 plays indispensable role in innate and adaptive immune defense against *Mtb* infection (Figure [2](#F2){ref-type="fig"}), production of IL-22 by NK cells can inhibit intracellular growth of *Mtb*through enhancing phagolysosomal fusion [@B42]. Interesting, IL-22 can be found in the membrane of mature CD4+ T effector cells and the direct interaction of these cells with Mtb-infected macrophages led to suppress intracellular bacterial growth [@B84]. However, the molecular mechanisms by which IL-22 inhibits intracellular growth of *Mtb* are to be determined. Recently, it was found that IL-22 induced calgranulin A expression that can enhance phagolysosomal fusion by increasing Rab7 expression and downregulatiing Rab14 expression [@B85].

IL-24, also known as melanoma differentiation associated gene 7 product(mda-7), has potent antitumor activity through selectively induced tumor death without detriment effect in normal cells [@B86]. Levels of IL-24 are significantly lower in the serum of TB patients in comparison with healthy volunteers [@B14]. IL-24 expression was decreased in PBMCs infected with Mtb, and addition of recombinant IL-24 can induce IFN-γproduction by CD8+ T cells [@B14].

IL-24 was significantly upregulated in PBMCs obtained from BCG-Japan strain-vaccinated children stimulated with culture filtrate proteins (CFP) of *Mtb* compared with children vaccinated with *BCG*-Brazil or *BCG*-Denmark strain [@B87]. PBMCs obtained from latent TB patients (LTB) produces more IL-24 than from active TB patients [@B88]. Furthermore, exogenous IL-24 can increase IFN-γin PBMCs obtained from TB patients, however, neutralization of IL-24 can reduce IFN-γexpression in PBMCs collected from LTB patients [@B46]. IL-24 increased IFN-γexpression through increasing expressions of IL-12, 1L-23 and IL-27, and by decreasing FOXP3 expression [@B46] (Figure [2](#F2){ref-type="fig"}). Taken together, *Mtb* suppresses IL-24 expression might enhance its persistence host tissue. However, underlying molecular mechanisms remain to be explored.

Conclusions
===========

In conclusion, IL-10 family of cytokines has diverse roles during *Mycobacteria* infection ranging from immune evasion to immune protective. The absence of IL-10 can enhance immune response and early clearance of *Mtb*. IL-10 can enhance the intracellular survival of bacilli via several means, namely 1) inhibiting phagosomal maturation, 2) reducing nitric oxide production and 3) blocking IFN-γsignaling in macrophage. In addition, IL-10 can antagonize the development of Th1 responses through suppressing antigen presentation and IL-12 production. Moreover, it can inhibit macrophages apoptosis that is require for efficient development of T cells responses. However, low level IL-10 can trigger antimicrobial response and prevent tissue damage. Therefore, decreasing the IL-10 level during TB therapy might benefit for the rapid clearance of bacteria.

IL-26 is a novel player with scarce information in TB immune responses; it can limit *Mtb* clearance during *in vitro*infection of PBMCs by mechanisms currently unknown. Understanding how IL-26 enhances intracellular growth of bacilli is critical to develop better countermeasures against this notorious pathogen.

IL-22 plays a decisive role in innate and adaptive immune responses against *Mtb*infection by promoting phagolysosomal fusion, expansion and IFN-γproduction by memory CD4+ cells and recruitment of B cells.

IL-24 induces IFN-γproduction by CD8+ T cells. IL-22 and IL-24, crucial for the coordinated cell-mediated immunity, might represent good candidates for better TB therapy.
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![***Mycobacterial* regulation of IL-10 family expression.***Mycobacterium tuberculosis*or*M.bovis*BCG can engage with PRR on the hematopoietic and non-hematopietic cells and result in the activation of downstream effectors and IL-10 expression. Receptors and signaling involved in the expression of IL-20 subfamily in response to *Mtb* infection is currently unknown. → Direct activation; ↵ = autocrine; ? = unknown](ijbsv12p0710g001){#F1}

![**Regulation of immune responses by IL-10 family cytokines during Mycobacteria infection:**IL-10 family of cytokines induced by *mycobacteria*infection modulates immune responses. IL-10 can enhance intracellular survival and growth of bacilli by inhibition nitric oxide production, phagosomal maturation and IFN-γ-mediating killing. In addition, IL-10 can inhibit CD4+ T cell responses by suppression of IL-12 production and trafficking of *Mtb*peptide-MHC-II complexes to the plasma membrane. It also suppresses T cells cross-priming by antigen-presenting cells via blocking macrophages apoptosis. IL-10 can modulate granuloma formation via inhibition of TNF-α, Th17 cells and T cells expansion. Il-26 enhances intracellular survival of Mtb by unknown mechanism. IL-26 can recruit neutrophils to site of battle that can cause tissue damage and suppression Th1 response. IL-26 also promotes binding of released bacterial DNA to the TLR9 in surface of plasmacytoid DC resulting in production type I IFN. IL-22 can inhibit intracellular growth of bacilli via enhancing phagolysosomal fusion. IL-22 is an important activator of adaptive immune responses through promoting the expansion of memory CD4+ cells and IFN-γ production and recruitment of B cells to site of infection. IL-24 induces IFN-γ production by CD8+ cells and suppresses FOXP3 T reg cells.](ijbsv12p0710g002){#F2}
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